Suppr超能文献

探讨 RPLP0、RPLP1 和 RPLP2 表达在肺腺癌中的功能和预后价值。

Exploring the function and prognostic value of RPLP0, RPLP1 and RPLP2 expression in lung adenocarcinoma.

机构信息

Department of Pulmonary and Critical Care Medicine, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Pudong, Shanghai, China.

Department of Outpatient, The Affiliated Hospital of Jiaxing University, The First Hospital of Jiaxing, Jiaxing, Zhejiang, China.

出版信息

J Mol Histol. 2024 Dec;55(6):1079-1091. doi: 10.1007/s10735-024-10251-z. Epub 2024 Aug 29.

Abstract

Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer (NSCLC) and is characterized by its heterogeneity and poor prognosis. The role of ribosomal proteins RPLP0, RPLP1 and RPLP2 in multiple cancers has been implicated. However, their function in LUAD and their correlation with the poor prognosis of LUAD remains elusive. In this study, we performed a comprehensive bioinformatic analysis of the impact of these ribosomal proteins on LUAD. Our findings reveal that RPLP0, RPLP1 and RPLP2 are overexpressed in LUAD, which are likely attributed to abnormal copy number variations and decreased methylation levels of their promoters. LUAD patients with high expression of RPLP0, RPLP1 or RPLP2 have worse clinical outcomes in terms of overall survival (OS), first progression (FP) and post-progression survival (PPS), indicating poor prognosis. Moreover, the expression of RPLP0, RPLP1 and RPLP2 affects immune cell infiltration in LUAD tissues. Finally, we identified multiple existing drugs that may inhibit the expression of RPLP1 and RPLP2. Collectively, our data implicate the oncogenic role of RPLP0, RPLP1 and RPLP2 in LUAD and underscore their prognostic value in LUAD patients.

摘要

肺腺癌 (LUAD) 是最常见的非小细胞肺癌 (NSCLC) 亚型,其特点是异质性和预后不良。核糖体蛋白 RPLP0、RPLP1 和 RPLP2 在多种癌症中的作用已经被涉及。然而,它们在 LUAD 中的功能及其与 LUAD 预后不良的相关性仍然难以捉摸。在这项研究中,我们对这些核糖体蛋白对 LUAD 的影响进行了全面的生物信息学分析。我们的研究结果表明,RPLP0、RPLP1 和 RPLP2 在 LUAD 中过度表达,这可能归因于异常的拷贝数变异和启动子甲基化水平降低。RPLP0、RPLP1 或 RPLP2 高表达的 LUAD 患者在总生存期 (OS)、首次进展 (FP) 和进展后生存期 (PPS) 方面的临床结局较差,表明预后不良。此外,RPLP0、RPLP1 和 RPLP2 的表达影响 LUAD 组织中的免疫细胞浸润。最后,我们确定了多种可能抑制 RPLP1 和 RPLP2 表达的现有药物。总之,我们的数据表明 RPLP0、RPLP1 和 RPLP2 在 LUAD 中具有致癌作用,并强调了它们在 LUAD 患者中的预后价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8e/11567986/5725b1638972/10735_2024_10251_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验